East Windsor, NJ, May 11, 2026 - Hovione today announced that Dr. Jean Luc Herbeaux has decided to step down from his role as Chief Executive Officer for personal reasons, effective as of May 21, 2026. To facilitate a smooth transition, Dr. Herbeaux will continue with the company until September 30, 2026.

The Board of Hovione Holding AG expressed its gratitude for Dr. Herbeaux’s transformational leadership and significant achievements during his tenure. Under his leadership, the company strengthened its market position, expanded capabilities, and continued to grow as a trusted partner to customers and broader stakeholders.

The Board has initiated a succession process to appoint the company´s new Chief Executive Officer. In the interim, and to ensure continuity of leadership and strategic execution, the Board has appointed António Almeida (currently Chief Financial Officer) and Dr. Marco Gil (currently Senior VP Sales & Marketing) as co-Chief Executive Officers, effective as of May 21, 2026.

Both executives are long-standing members of Hovione´s Global Leadership Team and have played key roles in the company´s growth and operations over many years. They bring extensive knowledge of the business, strong operational expertise, and established relationships across the organization, customers, and partners. They have the full confidence and support of the Board and the shareholders to continue successfully executing the company’s strategy.

“Hovione remains strongly positioned for the future, with a clear strategy, a strong leadership team, and a continued commitment to operational excellence and innovation,” said Dr. Stefan Doboczky, Chairman of the Board of Directors, Hovione. “We are confident in the company’s ability to continue delivering for customers, partners, and other stakeholders throughout this transition and beyond.”

Hovione confirmed that its strategic direction, business priorities, and commitments remain unchanged. The company continues to focus on supporting its customers and partners with innovative solutions across advanced chemistry, particle design, and finished dosage, while maintaining the highest standards of quality, reliability, and collaboration.